Abstract
Progress in the field of antiretroviral therapy for human immunodeficiency virus type 1 (HIV-1) infection has brought the end of the zidovudine-monotherapy era,
1
–
3
an improved understanding of the pathogenesis of HIV-1 disease,
4
–
9
demonstrations of the prognostic importance of plasma HIV-1 RNA quantification,
10
–
17
and the availability of increasingly potent therapeutic agents. Much of this progress is linked to the introduction of the HIV-protease inhibitors, drugs that inhibit the processing of Gag and Gag–Pol polyprotein precursors and thus prevent the maturation of virions.
18
–
20
Trials of HIV-protease inhibitors have shown beneficial effects on CD4 cell counts and plasma HIV-1 . . .
